Natriuretic peptides, extracellular volume, and subclinical cardiovascular changes in chronic kidney disease stages

L Parker Gregg1,2,3, Peter N Van Buren4,5, David J Ramsey3

  • 1Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA lucile.gregg@bcm.edu.

Insights

Elevated natriuretic peptides in early chronic kidney disease (CKD) stages 1-3 correlate with cardiovascular changes, not fluid overload. These biomarkers may detect subclinical heart issues in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarkers

Background:

  • Natriuretic peptide levels are elevated in early chronic kidney disease (CKD) stages 1-3.
  • The association with extracellular volume excess or early cardiovascular changes is unclear.

Purpose of the Study:

  • To investigate cardiovascular changes in patients with CKD stages 1-3.
  • To determine if these changes correlate with brain natriuretic peptide (BNP) and amino-terminal-pro-BNP (NT-pro-BNP) levels and patient-reported symptoms.

Main Methods:

  • Compared cardiovascular parameters (extracellular water, total peripheral resistance index, cardiac index) in CKD stages 1-3 patients and non-CKD controls.
  • Utilized whole-body multifrequency bioimpedance spectroscopy and impedance cardiography.
  • Assessed patient-reported symptoms using questionnaires.

Main Results:

  • CKD patients exhibited higher pulse pressure and total peripheral resistance index, with a lower cardiac index compared to controls.
  • Natriuretic peptides correlated with pulse pressure, cardiac index, and total peripheral resistance index, but not extracellular water.
  • Total peripheral resistance index and blood pressure showed moderate correlation with patient symptoms.

Conclusions:

  • Elevated natriuretic peptides in early CKD may indicate subclinical cardiovascular changes like low cardiac index and elevated peripheral resistance.
  • Further research is needed to explore the role of these biomarkers in detecting early cardiovascular alterations in CKD.

Related Concept Videos

Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
50
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
76
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
64